|

Capivasertib Clinical Trials

14 actively recruiting trials across 9 locations

▲ +1 trial since July 2026

Also known as: AZD5363, TRUQAP, Truqap

Pipeline

Phase 1: 2Phase 2: 6Phase 3: 3Phase 1/2: 3

Top Sponsors

  • AstraZeneca2
  • West German Study Group1
  • VA Office of Research and Development1
  • University of Chicago1
  • University of British Columbia1

Indications

  • Cancer14
  • Breast Cancer7
  • Metastatic Breast Cancer3
  • HER2-negative Breast Cancer2
  • Advanced Breast Cancer2

Other4 trials

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
Phase 2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
Phase 2
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Phase 3

Tucson, Arizona2 trials

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Research Site

Phase 3
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

University of Arizona

Phase 1/2

Birmingham, Alabama1 trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

University of Alabama at Birmingham Cancer Center

Phase 2

Gilbert, Arizona1 trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Banner MD Anderson Cancer Center

Phase 3

Rialto, California1 trial

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Research Site

Phase 1

Sacramento, California1 trial

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

University of California Davis

Phase 2

West Los Angeles, California1 trial

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Phase 2

New Haven, Connecticut1 trial

Rash & Diarrhea Prophylaxis With Capivasertib

Yale University

Phase 2

Chicago, Illinois1 trial

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

University of Chicago Medicine Comprehensive Cancer Center

Phase 1/2

Houston, Texas1 trial

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.